2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimates
2019
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers
Pusztai L, Foldi J, Dhawan A, DiGiovanna MP, Mamounas EP. Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers. The Lancet Oncology 2019, 20: e390-e396. PMID: 31267973, DOI: 10.1016/s1470-2045(19)30158-5.Commentaries, Editorials and LettersConceptsEarly-stage breast cancerHER2-positive breast cancerBreast cancerClinical trialsNeoadjuvant chemotherapyEstrogen receptor-negative breast cancerImproved disease-free survivalReceptor-negative breast cancerParticular chemotherapy regimenResidual invasive cancerNeoadjuvant systemic therapyDisease-free survivalImportant clinical trialsAdo-trastuzumab emtansineNegative breast cancerAdjuvant settingKATHERINE trialOperable diseasePostoperative capecitabineChemotherapy regimenMetastatic diseaseSystemic therapyResidual diseaseInvasive cancerTreatment sequencing
2013
USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer
Bayraktar S, Barrera A, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. The Cancer Journal 2013, 19: 10-17. PMID: 23337751, PMCID: PMC3568679, DOI: 10.1097/ppo.0b013e3182801b3a.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPathological complete responseBreast cancerKaplan-Meier product-limit methodBetter survival outcomesDisease-free survivalOverall survival rateRisk of recurrenceProduct-limit methodLogistic regression modelsNeoadjuvant therapyComplete responsePrognostic factorsSystemic therapyDisease recurrencePrognostic relevanceSurvival outcomesHigh riskPatientsSurvival rateTumorsCancerRecurrencePolymerase inhibitionUbiquitin-specific protease family
2012
Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer
Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer. Clinical Cancer Research 2012, 18: 1109-1119. PMID: 22235097, PMCID: PMC3288822, DOI: 10.1158/1078-0432.ccr-11-2762.Peer-Reviewed Original ResearchConceptsResidual cancerBreast cancerAdjuvant treatment strategiesNeoadjuvant systemic therapyLike breast cancerBasal-like cancersSmall G proteinsCalmodulin-dependent protein kinase IICancer stem cell signaturesEnergy metabolismFine-needle aspiration specimensGene expression differencesEpithelial-mesenchymal transitionSonic hedgehog (Shh) signalingNeedle aspiration specimensProtein kinase IIImmune-related pathwaysNew therapeutic insightsGene expression dataStem cell signatureSonic hedgehog pathwaySystemic therapy
2011
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals Of Surgical Oncology 2011, 19: 1508-1516. PMID: 22193884, DOI: 10.1245/s10434-011-2108-2.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPrimary breast cancerBreast cancerSystemic therapyBreast-conserving surgery rateLarge adjuvant trialsPathologic complete responseInflammatory breast cancerNew therapeutic regimensIntermediate end pointsInternational Consensus ConferenceClinical research groupAdjuvant trialsNew regimensPathologic responseComplete responseSurgery ratesTherapeutic regimensConsensus conferenceEnd pointTherapyCancerTrialsRegimensPanel of representativesResponse to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Arun B, Bayraktar S, Liu DD, Barrera A, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. Journal Of Clinical Oncology 2011, 29: 3739-3746. PMID: 21900106, PMCID: PMC4874218, DOI: 10.1200/jco.2011.35.2682.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic chemotherapyRelapse-free survivalBreast cancerOS ratesOverall survivalBRCA1 carriersBRCA statusBRCA2 mutationsKaplan-Meier product-limit methodPathologic complete response rateComplete response rateNeoadjuvant systemic therapySingle institution experienceEstrogen receptor negativityBRCA mutation carriersBRCA1 statusIndependent significant predictorsProduct-limit methodMultivariate logistic modelBRCA genetic testingSporadic breast cancerLogistic regression modelsBRCA noncarriersTrastuzumab useSystemic chemotherapy